{
  "pmid": "39641926",
  "pmc_id": "11624585",
  "n_tables": 3,
  "keywords": [
    "dpyd",
    "ugt1a1",
    "fluoropyrimidine",
    "irinotecan",
    "toxicity",
    "grade"
  ],
  "hit_tables": [
    {
      "label": "Table 1.",
      "title": "Frequency of Genotype-Based Phenotypes and Recommended Dose Adjustments",
      "text": "Table 1. Frequency of Genotype-Based Phenotypes and Recommended Dose Adjustments Patients treated with fluoropyrimidines and/or irinotecan a Control arm (n = 311), No. (%) Intervention arm (n = 252) No. (%) Pharmacogenetic-informed treatment according to DPWG guidelines Actionable genotype carriers 23 (7.4) 17 (6.7) DPYD AS 0.5 1 (0.3) 0 Avoid fluoropyrimidines or perform DPD phenotyping DPYD AS 1 6 (1.9) 2 (0.8) 50% of the standard dosage DPYD AS 1.5 7 (2.3) 11 (4.4) 50% of the standard dosage UGT1A1 PM 9 (2.9) 4 (1.6) 70% of the standard dosage Nonactionable genotype carriers ( DPYD AS 2, UGT1A1 NM/IM) 288 (92.6) 235 (93.3) Standard dosage Abbreviations: AS, activity score; DPD, dihydropyrimidine dehydrogenase; DPWG, Dutch Pharmacogenetics Working Group; IM, intermediate metabolizer; NM, normal metabolizer; PM, poor metabolizer. a Activity scores for DPYD and metabolizer status for UGT1A1 were assigned based on PharmGKB Clinical Guideline Annotations. 30"
    },
    {
      "label": "Table 2.",
      "title": "Difference in the Incidence of Clinically Relevant Toxic Effects Between Arms a",
      "text": "Table 2. Difference in the Incidence of Clinically Relevant Toxic Effects Between Arms a Variable Patients, No. Patients with clinically relevant toxic effects, No. (%) OR (95% CI) b P value b Any actionable genotype carriers Control arm 23 8 (34.8) 1 [Reference] .04 Intervention arm 17 1 (5.9) 0.1 (0.0-0.8) All patients Control arm 311 54 (17.4) 1 [Reference] .41 Intervention arm 252 37 (14.7) 0.8 (0.5-1.3) Subanalysis focusing only on the actionable DPYD genotype carriers Control arm 14 5 (35.7) 1 [Reference] .04 Intervention arm 13 0 NA Abbreviations: NA, not applicable; OR, odds ratio. a Gatekeeping analysis was conducted for patients with an actionable genotype and all patients, irrespective of genotype. b Multivariate logistic regression adjusted for age and sex."
    },
    {
      "label": "Table 3.",
      "title": "Difference in the Incidence of Patients Hospitalized for Toxic Effect Management and the Toxic Effect Management Costs",
      "text": "Table 3. Difference in the Incidence of Patients Hospitalized for Toxic Effect Management and the Toxic Effect Management Costs Variable Patients, No. Hospitalized patients, No. (%) OR (95% CI) a P value a Adjusted cost (95% CI), $ b P value a Any actionable genotype carriers Control arm 23 8 (34.8) 1 [Reference] .12 4159 (1510-6810) .004 Intervention arm 17 2 (11.8) 0.25 (0.04-1.42) 26 (0-312) All patients Control arm 311 41 (13.2) 1 [Reference] .79 50 (25-76) .11 Intervention arm 252 35 (13.9) 1.07 (0.66-1.73) 25 (3-48) Subanalysis focusing only on the actionable DPYD genotype carriers Control arm 14 5 (35.7) 1 [Reference] .26 4168 (1481-6854) .006 Intervention arm 13 2 (15.4) 0.34 (0.05-2.24) 23 (0-522) Abbreviation: OR, odds ratio. a Multivariate logistic regression adjusted for age and sex. b Cost description is based on quantile regression; costs reported at the 75th percentile."
    }
  ],
  "generated_at": "2026-01-04T09:45:19Z"
}